Navigation Links
NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
Date:4/29/2014

In an article published in The Lancet Oncology, an NCI (US National Cancer Institute), NCRI (UK National Cancer Research Institute), and EORTC (European Organisation for Research and Treatment of Cancer) working group outline a practical risk-management approach for effective integration of biomarkers into cancer clinical trials. Their work provides the international community with a set of common principles by which biomarkers can be integrated into clinical trials, exchange of data can be facilitated, quality promoted, and research accelerated while simultaneously respecting local approaches and legislation.

Their risk-assessment approach for designing and conducting cancer clinical trials include risks to patient safety, operational risks, and biomarker development risks, and for each risk they evaluate possible consequences, provide solutions along with examples of these as well as references to helpful resources. Concerning protocol design, the working group recommends items that a protocol should include as well as items that should be assessed during protocol development. For the conduct of the trial, they make recommendations for the close monitoring of variability in test results, and they also make recommendations for particular aspects following completion of the trial.

Dr. Jacqueline Hall, who coordinated this NCI, NCRI, and EORTC working group says, "We readily acknowledge that in today's clinical trial landscape, many stakeholders play a role in clinical trials. These include regulators, public authorities, and patients, amongst others. By opening this discussion to others, we hope to find solutions to the varied challenges facing molecularly driven clinical research."


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
2. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
5. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
6. EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
7. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
8. EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
9. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
10. EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
11. Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... As President Trump challenges the status quo ... administration could impact the employee benefits industry. James Slotnick, AVP, Government Relations, for ... make it through Congress. His discussion will focus on the current state of ...
(Date:4/25/2017)... NV (PRWEB) , ... April 25, 2017 , ... ... now choose a modern procedure that achieves results in a fraction of the ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS Healthcare Solutions ... (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. , BYOD ... devices with a pre-programmed tablet in a remarkably easy-to-use kit for patients. “BYOD ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology: